^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Gallbladder Cancer
    Regimen:GemOx (gemcitabine + oxaliplatin)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Neoadjuvant therapy (for gallbladder cancer only)…Other recommended regimens…Gemcitabine + oxaliplatin (category 2B)
    Evidence Level:
    Sensitive: B - Late Trials
    Source:
    Eur J Cancer
    Title:

    Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer: Results of a phase III randomised controlled trial

    Published date:
    12/01/2019
    Excerpt:
    Modified gemcitabine and oxaliplatin or gemcitabine + cisplatin in unresectable gallbladder cancer...Median OS in mGemOx was 9 months and 8·3 months in CisGem; p = 0·057 (hazard ratio = 0·78; 95% CI = 0·60-1·02). Restricted mean OS for follow-up limited to 30 months was 11·2 months (95% CI: 9·8–12·6) in mGemOx and 10·4 months (95% CI: 9·1–11·7) in CisGem....Numerically OS was better with mGemOx.
    DOI:
    doi.org/10.1016/j.ejca.2019.10.004